This is a service of EIN News a digital news provider
Healthcare Industry Today
Sign up for a free trial
Register Now
Member center Log In
Anthrax Drugs News is an EIN News Service for health professionals. Constantly updated news and information about health.
FORMATS: RSS | EMAIL

Latest Anthrax Drugs News

  • BioWatch: HGS seeks OK for hepatitis C treatment 26 Nov 2009 10:12 GMT
    ... federal regulatory approval to market its new treatment for hepatitis C. The Rockville biotech is ... could total $507.5 million, HGS said. The drug is made by genetically fusing human albumin, ... the FDA for more information about its anthrax treatment, for which the company seeks marketing ...

  • Less-Often Interferon Filing Done as HGS Revs Benlysta 26 Nov 2009 02:55 GMT
    ... the biologics license application filing for lupus drug Benlysta (belimumab), expected in the first half ... "confident interferons will be part of the treatment regimen for a long time to come." ... 2009.) Also in HGS' pipeline is the anthrax drug raxibacumab, which received a complete response ...

  • Human Genome Sciences Submits Biologics License Application to... 25 Nov 2009 19:09 GMT
    ... Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for ... (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission ... drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. The Company’s primary focus is ...

  • Human Genome Sciences submitted application for new drug Zalbin 25 Nov 2009 16:13 GMT
    ... year to federal regulators to sell a drug on the market, this most recent being for its hepatitis C treatment called Zalbin. With these applications, including a ... to the for approval to sell its anthrax treatment, though that submission hit a stumbling ...

  • Crown Equity Holdings, Inc.: CRWENews Highlights: HGSI, HWAY 25 Nov 2009 14:57 GMT
    ... Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN (albinterferon alfa-2b) for ... (FDA) for ZALBIN (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission ... drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. Healthways to Provide SilverSneakers Fitness ...

  • www.StockMarketingInc.com: Check Us Out!!! Sign Up Now For Our Free Newsletter!! HGSI,AFFX,CNQR,CONN,DMAN,DNDN 25 Nov 2009 14:57 GMT
    ... Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN(TM) (albinterferon alfa-2b) for ... (FDA) for ZALBIN(TM) (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission ... drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. The Company's primary focus is ...

  • AVANIR to Present at the Piper Jaffray Health Care Conference 25 Nov 2009 13:50 GMT
    ... and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead ... International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The ...

  • Human Genome Sciences Submits Biologics License Application to FDA for ZALBIN 25 Nov 2009 12:32 GMT
    ... Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN (albinterferon alfa-2b) for ... (FDA) for ZALBIN (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission ... drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. The Company's primary focus is ...

  • Human Genome Sciences Submits Biologics License Application to FDA for ZALBIN(TM) 25 Nov 2009 12:30 GMT
    ... Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN(TM) (albinterferon alfa-2b) for ... (FDA) for ZALBIN(TM) (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission ... drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. The Company's primary focus is ...

  • Human Genome Sciences Submits Biologics License Application to FDA for ZALBIN'¢ 25 Nov 2009 12:30 GMT
    ... Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for ... (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission ... drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. The Company's primary focus is ...

  • Human Genome Sciences Submits Biologics License Application to FDA for ZALBIN(TM) (BIZ) 25 Nov 2009 12:30 GMT
    ... combination with ribavirin, for use in the treatment of interferon-naive patients with chronic hepatitis C. ... responsibility for commercial manufacturing of the finished drug product. Clinical development, commercial milestone and other ... drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. The Company's primary focus is ...

  • Former Secretary Thompson Uses Clout In Health Care Debate Loading... 24 Nov 2009 23:30 GMT
    ... helped create the Medicare Part D prescription drug plan for seniors, increased federal spending on AIDS ... and led the agency during the post-9-11 anthrax outbreaks. Thompson's critics call Medicare Part D a ...

  • Former Secretary Thompson uses clout in health care debate [BC-HEALTHCARE-THOMPSON:MW] 24 Nov 2009 20:11 GMT
    ... helped create the Medicare Part D prescription drug plan for seniors, increased federal spending on AIDS ... and led the agency during the post-9-11 anthrax outbreaks. Thompson's critics call Medicare Part D a ...

  • AVANIR Pharmaceuticals Announces Fiscal 2009 Fourth Quarter and Full Year Financial Results 24 Nov 2009 13:50 GMT
    ... we made by advancing our promising investigational drug Zenvia(TM) through Phase III development in pseudobulbar ... met its primary efficacy endpoint in the treatment of PBA in the top-line results of ... International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The ...

  • Former Secretary Thompson uses clout in health care debate 24 Nov 2009 13:31 GMT
    ... helped create the Medicare Part D prescription drug plan for seniors, increased federal spending on AIDS ... and led the agency during the post-9-11 anthrax outbreaks. Thompson's critics call Medicare Part D a ...


1 - 15 / 97      NEXT >>>

Powered by Newsfeed Maker
NOT SATISFIED WITH THIS ANTHRAX DRUGS NEWS SECTION? MAKE YOUR OWN WITH THE INBOX ROBOT OR TRY OUR OTHER MEDIA MONITORING SERVICES.
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>>
 
 

Take This Poll

Is Belgian Prime Minister Herman Van Rompuy the right person to lead the EU as its president? (Nov. 20, 2009)



 

BUSINESS PROMOTION SERVICES

EIN Advertising · Place banner ads on EIN News industry specific publications.

EIN Presswire · Upload press releases to the EIN network and have them submitted to leading journalists and decision-makers worldwide.

EIN Global Events · Reach industry-specific readers and promote events, conferences or exhibitions.

EIN Business Directory · Present company or service information on highly-visible, industry and geo-specific news pages.

NEWS SERVICES

News Publications · In-depth geopolitical and industry specific news coverage aggregated from 35,000 online outlets. Updated every 15 minutes.

News Alerts · Receive a free selection of the day's top stories hand picked by EIN News editors.

Newsfeed Maker · Integrate customized newsfeeds in any format covering all industry and geopolitical topics, updated every 15 minutes.

EIN Presswire · Upload press releases to the EIN network and have them submitted journalists and decision-makers worldwide.

Inbox Robot · Customized newsletters delivered by e-mail. Search a news index monitoring thousands of trusted media sources.

COMPANY BACKGROUND

About EIN News · Established in 1995, EIN News began by supplying business professionals and individuals with relevant and interesting news products. It has grown to become the largest digital news provider in Europe.

Member List · See the partial member list and join a community of professionals from private industry, institutions, and governments that rely on EIN as a critical source for research, breaking news and media services.